We are pleased that there is interest in our study 1 Given the association of À2578 G with the advanced progression of several pathological conditions, understanding the transcriptional regulation of the À2578 single nucleotide polymorphism at a molecular level holds promise for strategic therapeutic intervention. The major finding reported in our paper was the identification of Prep1/Pbx2 complexes in an astrocytic cell line (classical producers of CCL2) that bind preferentially to the À2578 G allele.
The response to our paper by Mummidi et al. does not contest the evidence supporting our conclusions regarding Prep1/Pbx2, but rather focuses on the lack of evidence our data provided for the binding of interferon regulatory factor-1 (IRF-1) to À2578 A (or G) and hence interferon stimulatory response element (ISRE) activity of the À2578 single nucleotide polymorphism. Earlier, this group showed in supplemental data to Gonzalez et al.
2 that IRF-1 in nuclear extracts from the MG-63 osteoblastic cell line binds preferentially to the À2578 A allele. In the extended study accompanying their letter, they demonstrate that in vitro transcribed and translated IRF-1 can bind to À2578 A oligos including the À2578 A oligo used in our report. It is their view that the ability of in vitro transcribed and translated IRF-1 to bind À2578 A oligos indicates that the À2578 region functions as an ISRE, and as a consequence, the opposite conclusion reached in our study may need revision.
Relevant to our interest in HIV-D, our studies were carried out in U87-MG cells that exhibit the enhanced expression phenotype associated with À2578 G. We never observed endogenous (that is, produced naturally by the cell) IRF-1 in U87-MG nuclear extracts binding to À2578 A (or G) oligos even under conditions where endogenous IRF-1 clearly binds to ISRE oligos, and the À2578 G phenotype is maximal in our study. These data alone compel us to conclude that IRF-1 in U87-MG nuclear extracts binds to ISRE but not to À2578 A (or G) oligos, and it is therefore our view that the conclusions regarding IRF-1 and ISRE functions drawn directly from the data in our study are logical. Moreover, the robust binding of Prep1/Pbx2 complexes demonstrated in competition experiments provides strong evidence that the À2578 region functions far more like a MEINOX site than as an ISRE in U87-MG cells.
As stated above, understanding the molecular regulation of the À2578 single nucleotide polymorphism is key to understanding the pathogenesis of numerous conditions negatively impacted by the À2578 G allele. Because À2578 G is most often associated with increased expression of CCL2, a finding supported by Gonzalez et al., it is difficult, a priori, to conceptualize a molecular model (and none has been put forth to date in any cell type) where increased binding of IRF-1 (a classical transactivator) to the À2578 A allele would result in the lower expression of CCL2 relative to the À2578 G allele. In our studies of U87-MG cells, the data simply do not support a role for IRF-1; however, our identification of Prep1/Pbx2 complexes binding preferentially to À2578 G alleles in these cells coupled with previous reports on CCL2 in our SIV macaque model enabled us to propose the first molecular hypothesis to explain how À2578 G alleles could potentially accelerate the progression of HIV-D. 
